Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Fragile X disappointments upset autism ambitions

Nature Reviews Drug Discovery volume 14, pages 151–153 (2015)Cite this article

Subjects

The clinical failure of two large mGluR5-antagonist programmes in Fragile X syndrome has forced drug developers to rethink trial design and target selection for neurodevelopmental indications.

In September, Roche pulled the plug on its mGluR5 antagonist RG7090 in FXS, citing a lack of efficacy. Just 5 months earlier, Novartis had reported that its mGluR5 antagonist AFQ056 hadn't worked either and discontinued development in FXS. A smaller biotech, Seaside Therapeutics, who had partnered with Roche, discontinued trials of its own mGluR5 antagonist STX107 (and of its γ-aminobutyric acid type B receptor agonist STX209) nearly a year earlier when it ran out funding, and has since practically suspended its operations. What went wrong?

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. Fragile X disappointments upset autism ambitions. Nat Rev Drug Discov 14, 151–153 (2015). https://doi.org/10.1038/nrd4555

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4555

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing